論文・技術情報追加のお知らせ

1. FLT1 as a Protective Factor in Ischemic Stroke: Insights from Real-World Pharmacovigilance and Genetic Evidence.

虚血性脳卒中に対するFLT1が保護因子として判明

対象DB：FAERS

2. Abnormal coagulation indicators associated with beta-lactamantibacterial drug: a pharmacovigilance study based on the FAERS database.

βラクタム系抗菌薬使用で異常凝固指標リスク、特にセフォペラゾン/スルバクタムが顕著

対象DB：FAERS

3. Post-licensure safety of respiratory syncytial virus vaccines, Vaccine Adverse Event Reporting System, United States, May 2023-December 2024.

RSVワクチンの安全性評価でGBSや早産報告、妊娠中投与に注意

対象DB：FAERS,VAERS

4. Arthritis-Related Adverse Reactions of Dupilumab in Treatment of Chronic Rhinosinusitis.

デュピルマブ関連関節炎、CRSwNPや喘息でリスク高

対象DB：FAERS

5. Drug-induced interstitial lung disease: a pharmacovigilance study of twelve immunomodulatory and antineoplastic agents.

薬剤性間質性肺疾患、アミオダロンとレフルノミドでリスク高

対象DB：FAERS

6. Analysis of the relationship between antidepressants and seizures based on the food and drug administration's adverse event reporting system database.

抗うつ薬使用と発作リスク調査、ブプロピオンが最も高いリスクを示す

対象DB：FAERS

7. Respiratory, thoracic, and mediastinal adverse events associated with ticagrelor: A pharmacovigilance study based on FDA adverse event reporting system.

チカグレロール関連呼吸器系障害リスク、性別・体重で重篤化傾向

対象DB：FAERS

8. Update of safety profile of bile acid sequestrants: A real-world pharmacovigilance study of the FDA adverse event reporting system.

胆汁酸吸着剤の安全性評価で消化器系AEs顕著

対象DB：FAERS

9. Cardiovascular toxicity associated with sedative drug use: Post-market pharmacovigilance study with disproportionality analysis.

集中治療室の鎮静薬比較で心血管毒性が顕著

対象DB：FAERS,VigiBase

10. Adverse events following 9-valent human papillomavirus vaccine (GARDASIL(R) 9) reported to the Vaccine Adverse Event Reporting System (VAERS), 2015-2024.

ガーダシル9の安全性確認、稀な副作用ポストマーケティング分析で検出

対象DB：FAERS,VAERS

11. Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System.

フィナステリド投与経路とPFS関連AEs分析、経口より局所投与でリスク低

対象DB：FAERS

12. Dupilumab adverse reactions in eosinophilic esophagitis treatment: a Food and Drug Administration Adverse Event Reporting System database analysis.

デュピルマブのEoE治療で安全性良好、注射部位・消化器反応が多い

対象DB：FAERS

13. Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS).

HCQ/CQ使用で網膜変性や黄斑浮腫など眼障害リスク高

対象DB：FAERS

14. Trimethoprim/sulfamethoxazole and risk of haemophagocytic lymphohistiocytosis (HLH): a literature review and disproportionality analysis using individual case safety reports from FAERS.

トリメトプリム/スルファメトキサゾールとHLHの関連示唆、男性優位

対象DB：FAERS

15. Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database.

エフガルチグモドアルファの実世界での安全性評価

対象DB：FAERS

16. Unveiling Aducanumab's safety profile: A comprehensive pharmacovigilance analysis.

アデュカヌマブの安全性評価で神経系副作用と予期せぬ反応確認

対象DB：FAERS

17. Psychiatric safety associated with hormone replacement therapy for menopausal symptoms: a real-world study of the FDA adverse event reporting system.

HRTの精神的副作用、年齢・投与経路・治療法でリスク差

対象DB：FAERS

18. Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis.

オマリズマブ使用後の脱毛症、特に女性で稀発生、自己免疫型一過性の可能性

対象DB：FAERS

19. Seasonal Variations in Drug-Related Erythema Multiforme: A Time Series Analysis Using the JADER Database.

薬剤性紅斑性丘疹、男女で季節差あり、春～夏に発症ピーク6月

対象DB：JADER

20. Post-marketing safety analysis of blonanserin: a retrospective pharmacovigilance study using the Japanese Adverse Drug Event Report database (2008-2024).

ブロナンセリンの早期発現副作用確認

対象DB：JADER

21. Flunitrazepam increases the risk of lamotrigine-induced cutaneous adverse reactions: Combined analysis of medical big data and clinical research.

フルニトラゼパム併用でラモトリギン濃度上昇、発疹リスク増加の可能性

対象DB：VigiBase

22. Epidemiology and outcomes of septic shock in Japan: a nationwide retrospective cohort study from a medical claims database by the Japan Sepsis Alliance (JaSA) study group.

日本における敗血性ショック、過去10年で生存率改善も高い致死率と大規模医療負担継続

対象DB：DPC

23. Poor Prognostic Factors of Cervical Fracture among Nonagenarians Using the Japanese Diagnosis Procedure Combination Database.

90歳超の頸椎骨折、死亡率15.5%、頭部損傷・合併症で予後悪化

対象DB：DPC

24. Postoperative pulmonary complications of desflurane- versus sevoflurane-based general anesthesia in patients with chronic obstructive pulmonary disease or asthma undergoing gastrointestinal cancer surgery: a nationwide retrospective cohort study.

デスフルラン、COPD・喘息患者の術後肺合併症リスク増加せず、セボフルランと類似

対象DB：DPC

25. Cardiac arrhythmias in cancer patients using the nationwide claim-based database in Japan.

癌患者の不整脈、AF/AFLが最多、合併症や緊急入院頻度で非癌患者と相違

対象DB：DPC

26. Mortality of severe pneumonia treated with methylprednisolone versus hydrocortisone: a propensity-matched analysis.

重症肺炎、メチルプレドニゾロンが敗血性ショック患者で死亡率低下の可能性

対象DB：DPC

27. Incidence and Risk Factors for Serious Infections in Patients with Neuromyelitis Optica Spectrum Disorder: A Claims Database Study in Japan.

NMOSD患者における重篤な感染症のリスク要因、年齢・併存疾患・治療選択が影響

対象DB：MDV

28. Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan.

日本におけるCOPD治療、FF/UMEC/VIとMITTでCAP入院リスク差なし

対象DB：MDV

29. In-silico trials of targeted screening for abdominal aortic aneurysms using linked healthcare data: A study protocol.

AAA標的スクリーニング、臨床・経済効果向上の可能性を探る

対象DB：CPRD

30. Optimal risk-assessment scheduling for primary prevention of cardiovascular disease.

個別化・年齢特化のCVDリスク評価間隔、低リスク者は5年以上推奨可

対象DB：CPRD

31. Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.

GLP-1 RAs、SGLT-2阻害剤と比較しGERDおよび合併症リスク増加

対象DB：CPRD

32. Risk of Acute Infections in New Users of Antihypertensive Drugs: An Observational Cohort Study.

アムロジピン、急性感染リスク低下の可能性

対象DB：CPRD

33. Predicting clozapine-induced adverse drug reaction biomarkers using machine learning.

機械学習でクロザピン誘発無顆粒球症を予測、安全性向上に寄与

対象DB：CVAR

34. Association between ramelteon use and risk of fragility fractures: A retrospective cohort study.

長期作用型GnRHaの副作用解析、安全性プロフィールに差

対象DB：DeSC

35. Prevalence, Diagnosis, and Treatment of Generalized Anxiety Disorder in Working Individuals: A Cross-Sectional Study Using Health Claims and Survey Data in Japan.

日本におけるGADの高い有病率と医療行動の課題、啓発が必要

対象DB：DeSC

36. Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study.

ロモソズマブ、テリパラチドより骨関節炎リスク低減、特に膝で有効

対象DB：DeSC